Literature DB >> 16964578

Anthrax vaccines: Pasteur to the present.

A Scorpio1, T E Blank, W A Day, D J Chabot.   

Abstract

Anthrax has been a major cause of death in grazing animals and an occasional cause of death in humans for thousands of years. Since the late 1800s there has been an exceptional international history of anthrax vaccine development. Due to animal vaccinations, the rate of infection has dropped dramatically. Anthrax vaccines have progressed from uncharacterized whole-cell vaccines in 1881, to pXO2-negative spores in the 1930s, to culture filtrates absorbed to aluminum hydroxide in 1970, and likely to recombinant protective antigen in the near future. Each of these refinements has increased safety without significant loss of efficacy. The threat of genetically engineered, antibiotic and vaccine resistant strains of Bacillus anthracis is fueling hypothesis-driven research and global techniques--including genomics, proteomics and transposon site hybridization--to facilitate the discovery of novel vaccine targets. This review highlights historical achievements and new developments in anthrax vaccine research.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16964578     DOI: 10.1007/s00018-006-6312-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  18 in total

Review 1.  New insights into the biological effects of anthrax toxins: linking cellular to organismal responses.

Authors:  Annabel Guichard; Victor Nizet; Ethan Bier
Journal:  Microbes Infect       Date:  2011-09-08       Impact factor: 2.700

Review 2.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 3.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

Review 4.  Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Richard B Kennedy; Iana H Haralambieva; Robert M Jacobson
Journal:  OMICS       Date:  2011-07-06

5.  Protective antibody response following oral vaccination with microencapsulated Bacillus Anthracis Sterne strain 34F2 spores.

Authors:  Jamie Benn Felix; Sankar P Chaki; Yi Xu; Thomas A Ficht; Allison C Rice-Ficht; Walter E Cook
Journal:  NPJ Vaccines       Date:  2020-07-10       Impact factor: 7.344

6.  Murine innate immune response to virulent toxigenic and nontoxigenic Bacillus anthracis strains.

Authors:  Melissa Drysdale; Gwyneth Olson; Theresa M Koehler; Mary F Lipscomb; C Rick Lyons
Journal:  Infect Immun       Date:  2007-01-22       Impact factor: 3.441

7.  Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.

Authors:  Qin Li; Kristina K Peachman; Laurie Sower; Stephen H Leppla; Sathish B Shivachandra; Gary R Matyas; Johnny W Peterson; Carl R Alving; Mangala Rao; Venigalla B Rao
Journal:  Open Vaccine J       Date:  2009

8.  Saccharides cross-reactive with Bacillus anthracis spore glycoprotein as an anthrax vaccine component.

Authors:  Joanna Kubler-Kielb; Evgeny Vinogradov; Haijing Hu; Stephen H Leppla; John B Robbins; Rachel Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-18       Impact factor: 11.205

9.  Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.

Authors:  Melissa L Nguyen; Sherry R Crowe; Sridevi Kurella; Simon Teryzan; Brian Cao; Jimmy D Ballard; Judith A James; A Darise Farris
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

10.  The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-Specific CD4+ T cells with a phenotype distinct from that of naive PA T cells.

Authors:  William W Kwok; Junbao Yang; Eddie James; John Bui; Laurie Huston; Andrew R Wiesen; Michelle Roti
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.